Antisense oligonucleotides (ASOs), used to treat genetic diseases, can affect how cells repair damage to their DNA. This is ...

Therna Biosciences has joined forces with Charles River to advance single-patient RNA medicines for individuals with severe, ultra-rare disorders.

In this interview, Professor Anne Willis discusses her research on posttranscriptional control of gene expression and shares insights into the challenges faced by women in STEMM and highlights her ...

Camp4 Therapeutics FY25 GAAP EPS missed expectations, but ended the year with a robust cash position. Check out why CAMP ...

AcuraStem, a patient-based biotechnology company developing disease-modifying therapies for amyotrophic lateral sclerosis (ALS), today announced it has received a two-year research grant from Target ...

The oligonucleotides market offers opportunities in therapeutic applications, particularly for untreated diseases using ASOs, siRNA, and aptamers, with leaders like Alnylam driving innovation. Growth ...

The FDA proposes new rules allowing mutation-specific gene therapies to qualify for approval despite extremely small patient ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Nanocarriers enhance peptide and oligonucleotide therapy by improving stability, bioavailability, and targeted delivery for effective clinical applications.

Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with ...

Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development challenges.